Japan's Mitsubishi Tanabe posted reduced profit like-for-like in the first half of the fiscal year ending in March, 2009, due to 4.7 billion yen ($47.5 million) of pay-outs to employees who opted for early retirement.
Net profit fell 19.5% to 16.38 billion yen, in part because of the above exceptional costs, but also an 18% increase in R&D expenses to 37.62 billion yen, artificial sales increases caused by stock build-ups in the previous year and a drop in revenue.
Turnover dipped 0.7% to 206.34 billion yen, primarily consisting of pharmaceutical sales of 190.95 billion yen, which were down 1%. The firm says this was mainly due to National Health Insurance price revisions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze